Relating In Vitro Neutralization Level and Protection in the CVnCoV (CUREVAC) Trial

Deborah Cromer; Arnold Reynaldi; Megan Steain; James A Triccas; Miles P Davenport; David S Khoury

doi:10.1093/cid/ciac075

Relating In Vitro Neutralization Level and Protection in the CVnCoV (CUREVAC) Trial

Clin Infect Dis. 2022 Aug 24;75(1):e878-e879. doi: 10.1093/cid/ciac075.

Authors

Deborah Cromer¹, Arnold Reynaldi¹, Megan Steain^{2

3}, James A Triccas^{2

3}, Miles P Davenport¹, David S Khoury¹

Affiliations

¹ Kirby Institute, University of New South Wales, Sydney, Australia.
² School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
³ Sydney Institute of Infectious Diseases and Charles Perkins Centre, The University of Sydney, Sydney, New South Wales, Australia.

Abstract

The vaccine candidate CVnCoV (CUREVAC) showed surprisingly low efficacy in a recent phase 3 trial compared with other messenger RNA (mRNA) vaccines. Here we show that the low efficacy follows from the dose used and the presence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants and is predicted by the neutralizing antibody response induced by the vaccine.

Publication types

Clinical Trial
Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Neutralizing
Antibodies, Viral
COVID-19 Vaccines
COVID-19* / prevention & control
Humans
SARS-CoV-2
Viral Vaccines*

Substances

Antibodies, Neutralizing
Antibodies, Viral
COVID-19 Vaccines
Viral Vaccines